Clinical Trial

Efficacy and Safety of Brivudine in the Treatment of Herpes Zoster

Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
This multicenter RCT aims to compare the efficacy and safety of Brivudine versus Famciclovir in treating acute herpes zoster. Primary objective: Evaluate pain reduction via Numeric Pain Rating Scale (NPRS) at Day 30. Secondary objectives: Compare NPRS at Day 3/Day 7/Day 14/Day 90, time to lesion resolution, Postherpetic Neuralgia (PHN) incidence, and safety.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-25.
Status change: Not Yet Recruiting → Recruiting 2025-12-28
Trial Details
NCT Number NCT07099157
Lead Sponsor Peking University Third Hospital
Collaborators: Peking University First Hospital, Air Force Military Medical University, China, Beijing Hospital of Traditional Chinese Medicine, Xuanwu Hospital, Beijing
Conditions Herpes Zoster
Enrollment 140 participants
Start Date 2025-08-25
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-01-02